Jazz Pharmaceuticals plc (JAZZ) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $252.16. The rating moved from Oversold to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$252.16
• Last changeMoved from Oversold to Overbought on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Jazz Pharmaceuticals plc (JAZZ) combines a stable commercial franchise in specialty CNS/sleep medicines with pipeline and M&A optionality. The company’s cash generation and balance sheet support continued investment in R&D and strategic transactions, and an environment of elevated biotech multiples could provide constructive valuation tailwinds. Near‑term market conditions are muted with steady risk appetite, which favors relative stability for a healthcare name with recurring revenues. Key upside drivers include successful pipeline progress, accretive deals, and continued reimbursement stability; downside stems from payer margin pressure, competitive entry, regulatory setbacks, and execution on business development.

Key factors

• Established commercial portfolio in central nervous system and specialty sleep medicines providing steady revenue and cash flow
• Pipeline assets and recent inorganic opportunities broaden growth optionality and increase strategic value in an active biotech M&A market
• Favorable sector themes for specialty biologics and elevated M&A multiples that can support valuation upside for well‑positioned pharma targets
• Solid balance sheet and cash generation that can fund R&D, potential tuck‑ins, and shareholder returns
• Defensive investor flows into healthcare amid mixed market action, supporting relative stability versus high‑beta growth names
• Limited short‑term macro/news catalysts in the current window, reducing volatility from external headlines

Risks

• Payer pressure and MA plan rationalization that could compress reimbursement and reduce pricing power for branded therapies
• Regulatory and clinical trial risk on pipeline or label changes that would materially affect future revenue
• Competition from branded and generic entrants or alternative therapeutic modalities that could erode market share
• Execution risk around integration of acquisitions, R&D timelines, and commercialization of new products
• Valuation sensitivity if broader biotech sentiment reverses or if M&A multiples contract
• Limited social sentiment data and sparse real‑time news increases uncertainty about market perception and short‑term flows

Latest MarketMoodz coverage

• Jazz Taps AbCellera to Build T‑Cell Multispecific Oncology Pipeline2026-06-17

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.